Pfizer

Pfizer and Astellas Pharma has announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK…

According to GlobalData’s latest report, there is set to be a smaller proportion of global drug sales which will have patent…

Under the terms of the agreement, 3SBio will grant Pfizer an exclusive global license to develop, manufacture and commercialise…

Chakravarthi AVPS delivers special address on drug safety and moderates key discussion at PHARMAP 2025, shaping the future of…

GlobalData analyst highlights Leqselvi’s high-dose advantage and renewed market entry as key drivers for swift adoption, despite…

Dr Seema Pai to lead ISCR as it marks 20 years, with new appointments to General Secretary and Treasurer roles

European Commission amends marketing authorisation for Pfizer’s ABRYSVO vaccine, extending RSV protection to adults 18 and older…

US pharma manufacturing sees investment surge amid tariff shifts, while BRICS nations push regulatory reforms to expand biosimilar…

The initiative, driven by Cancer Research and Statistic Foundation and supported by AstraZeneca, Pfizer and Roche, and lab partner…

Additional follow-up from the Phase 3 study shows sustained overall survival benefit of enfortumab vedotin and pembrolizumab…